Revised forecast
Fiscal year ending March 2027 · Second quarter (interim period) and full yearPrevious forecast published 13 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
This was because results in the measuring and weighing instruments business and the medical and healthcare equipment business remained strong, while net sales and profit for the first half exceeded the initial forecasts due to factors including a refund of US tariffs and the impact of foreign exchange rates. Full-year forecasts were revised based on the latest outlook, including current results and demand forecasts for the period ahead.
| Item | Details |
|---|---|
| Net Sales | ¥68,000 million → ¥70,000 million（+2.9%） |
| Operating profit | ¥7,000 million → ¥8,000 million（+14.3%） |
| Ordinary income | ¥6,900 million → ¥8,200 million（+18.8%） |
| Profit attributable to owners of the parent | ¥4,500 million → ¥5,500 million（+22.2%） |
| Net income per share | ¥164.31 yen → ¥200.82 yen |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Second quarter (interim period) and full year |
| Publication date of previous forecast | 13 May 2026 |
| Previous-period results | Fiscal year ending March 2026: net sales ¥69,326 million, operating profit ¥9,209 million, ordinary profit ¥9,470 million, profit attributable to owners of the parent ¥5,923 million, earnings per share ¥216.33 |
| Reason for the revision | This was because results in the measuring and weighing instruments business and the medical and healthcare equipment business remained strong, while net sales and profit for the first half exceeded the initial forecasts due to factors including a refund of US tariffs and the impact of foreign exchange rates. Full-year forecasts were revised based on the latest outlook, including current results and demand forecasts for the period ahead. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This was because results in the measuring and weighing instruments business and the medical and healthcare equipment business remained strong, while net sales and profit for the first half exceeded forecasts due to factors including a refund of US tariffs and the impact of foreign exchange rates. Full-year forecasts were revised based on the latest outlook, including current results and demand forecasts for the period ahead.